A follow up study using the SECURE-IBD registry (now including 1439 IBD cases from 47 countries) was just recently published and now found that thiopurine, either as monotherapy or in combination with TNF-blockers, might increase the risk for severe disease course upon infection with SARS-CoV2 when compared to anti-TNF-monotherapy.58 Here, TNF is linked to irritable bowel syndrome.